Last reviewed 2026-04-23 · How we verify

AC-170 0%

AC-170 is a small molecule that targets the SGLT2 receptor.

AC-170 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.

At a glance

Mechanism of action

By inhibiting the SGLT2 receptor, AC-170 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.

Approved indications

• Type 2 diabetes

Common side effects

• Nausea
• Diarrhea
• Vomiting

Key clinical trials

• An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases (PHASE1)
• Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) (PHASE2)
• REmission in Membranous Nephropathy International Trial (REMIT) (PHASE3)
• Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement (PHASE2)
• Organ Protective Effect of Cetirizine In Patients With Severe Burns (PHASE1, PHASE2)
• Transporters for Organic Cations and Glycemic Control in Patients With Neuropathic Pain. (PHASE4)
• A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle (PHASE3)
• A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.